AdvaMed Comment Letter to OIG – January 27, 2023
AdvaMed responded to HHS OIG’s annual solicitation of proposals for new and modified safe harbors and special fraud alerts.
Letter to the Editor: Article on Device Sterilization Didn’t Provide the Complete Picture
Lucy Fraiser, Ph.D., a board-certified toxicologist, recently responded in a letter to the editor of Modern Healthcare about the publication’s recent coverage of the EPA’s work on ethylene oxide.
AdvaMed Submits Comments on CY 2023 OPPS/ASC Proposed Rule
AdvaMed submitted comments to CMS on the CY 2023 Hospital Outpatient Prospective Payment System and Ambulatory Surgical Center Payment System proposed rule.
AdvaMed Submits Comments on the CY 2023 PFS Proposed Rule
AdvaMed submitted comments to CMS on the Calendar Year 2023 Physician Fee Schedule (PFS) proposed rule.
AdvaMed Responds to CMS’ Request for Information Regarding Medicare Advantage
AdvaMed submitted a letter to CMS’s RFI on Medicare regarding ways to strengthen the Medicare Advantage program to align with the Vision for Medicare and CMS’ Strategic Pillars.
AdvaMed Submits Comments on CY 2023 ESRD PPS Proposed Rule
AdvaMed submitted comments to CMS the CY 2023 End Stage Renal Disease (ESRD) Prospective Payment System.
AdvaMed Submits Comments on Genetic Testing in Oncology LCD
AdvaMed submitted a letter to Medicare Administrative Contractors, Novitas and First Coast Service Options, regarding proposed LCDs on Genetic Testing in Oncology.
AdvaMed Submits Comments on FY 2023 IPPS Proposed Rule
AdvaMed submitted comments to CMS on the Fiscal Year 2023 Hospital Inpatient Prospective Payment System proposed rule.
AdvaMed Comments on Proposed Delay of Radiation Oncology Model
AdvaMed submitted comments to the Center for Medicare and Medicaid Services (CMS) on its Radiation Oncology (RO) Model proposed rule proposing to indefinitely delay the start date of the RO…
AdvaMed Submits Comments on Local Coverage Determination of Skin Substitutes
AdvaMed submitted a letter regarding proposed local coverage determinations entitled “Skin Substitutes for the Treatment of Diabetic Foot Ulcers and Venous Leg Ulcer.”